Stem cells’ guided gene therapy of cancer: New frontier in personalized and targeted therapy

Journal Title: Journal of Cancer Research & Therapy - Year 2014, Vol 2, Issue 1

Abstract

Diagnosis and therapy of cancer remain to be the greatest challenges for all physicians working in clinical oncology and molecular medicine. The grim statistics speak for themselves with reports of 1,638,910 men and women diagnosed with cancer and nearly 577,190 patients passed away due to cancer in the USA in 2012. For practicing clinicians, who treat patients suffering from advanced cancers with contemporary systemic therapies, the main challenge is to attain therapeutic efficacy, while minimizing side effects. Unfortunately, all contemporary systemic therapies cause side effects. In treated patients, these side effects may range from nausea to damaged tissues. In cancer survivors, the iatrogenic outcomes of systemic therapies may include genomic mutations and their consequences. Therefore, there is an urgent need for personalized and targeted therapies. Recently, we reviewed the current status of suicide gene therapy for cancer. Herein, we discuss the novel strategy: genetically engineered stem guided gene therapy. Stem cells have the unique potential for self-renewal and differentiation. This potential is the primary reason for introducing them into medicine to regenerate injured or degenerated organs, as well as to rejuvenate aging tissues. Recent advances in genetic engineering and stem cell research have created the foundations for genetic engineering of stem cells as the vectors for delivery of therapeutic transgenes. Specifically in oncology, the stem cells are genetically engineered to deliver the cell suicide inducing genes selectively to the cancer cells. Expression of the transgenes kills the cancer cells, while leaving healthy cells unaffected. Herein, we present various strategies to bioengineer suicide inducing genes and stem cell vectors. Moreover, we review results of the main preclinical studies and clinical trials. However, the main risk for therapeutic use of stem cells is their cancerous transformation. Therefore, we discuss various strategies to safeguard stem cell guided gene therapy against iatrogenic cancerogenesis. Defining cancer biomarkers to facilitate early diagnosis, elucidating cancer genomics and proteomics with modern tools of next generation sequencing, and analyzing patients’ gene expression profiles provide essential data to elucidate molecular dynamics of cancer and to consider them for crafting pharmacogenomics-based personalized therapies. Streamlining of these data into genetic engineering of stem cells facilitates their use as the vectors delivering therapeutic genes into specific cancer cells. In this realm, stem cells guided gene therapy becomes a promising new frontier in personalized and targeted therapy of cancer.

Authors and Affiliations

Mavroudi M, Zarogoulidis P, Porpodis K, Kioumis I, Lampaki S, Yarmus L, Malecki R

Keywords

Related Articles

The implementation of randomized trials in the treatment of advanced ovarian cancer with HIPEC: waiting for new evidence

Ovarian cancer (OC) is one of the most frequent mortality causes among female neoplasms. A lot of data is available on the efficiency and the relative safety of the different treatments. In the last twenty years the over...

The clinical and biological implications of the focal adhesion kinase pathway in ShenLingLan mediated suppression of cellular migration of ovarian cancer cells

The incidence of ovarian cancer in the UK has increased by almost twenty percent since the 1970’s and the majority of cases are not diagnosed until the late stages, when metastasis is more likely to have occurred. Focal...

Impact of neoadjuvant chemoradiation therapy on the postoperative complication rate in rectal cancer

Purpose: The impact of neoadjuvant chemoradiation therapy (CRT) on the postoperative complication rate is discussed controversially. Thus the aim of this study was to evaluate the postoperative complication rate in our p...

Development of a new formulation of interferons (HEBERPAG) for BCC treatment

Purpose: This work is aimed to show briefly, the clinical development of a new pharmaceutical formulation of interferons for the treatment of basal cell carcinoma. Methods: A rationale design of the combination of IFN-α2...

Anatomic categorization of gastrointestinal malignancies using haematoxylin and eosin stains: A 10-year retrospective histopathological study at the Korle-Bu Teaching Hospital Accra

Background: Data on gastrointestinal (GI) malignancies in Ghana are relatively uncommon and are mostly on colorectal cancers. The aim of this descriptive study was to categorize gastrointestinal tract malignancies accord...

Download PDF file
  • EP ID EP547301
  • DOI 10.14312/2052-4994.2014-4
  • Views 67
  • Downloads 0

How To Cite

Mavroudi M, Zarogoulidis P, Porpodis K, Kioumis I, Lampaki S, Yarmus L, Malecki R (2014). Stem cells’ guided gene therapy of cancer: New frontier in personalized and targeted therapy. Journal of Cancer Research & Therapy, 2(1), 22-23. https://europub.co.uk./articles/-A-547301